Premium
Case of chronic‐phase chronic myelogenous leukemia with an abdominal hematopoietic tumor of leukemic clone origin
Author(s) -
Sakakura Miho,
Ohishi Kohshi,
Nomura Kenichi,
Katayama Naoyuki,
Nishii Kazuhiro,
Masuya Masahiro,
Nakase Kazunori,
Shiku Hiroshi
Publication year - 2004
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.20165
Subject(s) - chronic myelogenous leukemia , fluorescence in situ hybridization , medicine , imatinib mesylate , clone (java method) , pathology , imatinib , bone marrow , lymph node , cd34 , leukemia , breakpoint cluster region , gene rearrangement , philadelphia chromosome , cancer research , immunology , biology , chromosomal translocation , stem cell , myeloid leukemia , chromosome , gene , biochemistry , genetics , receptor
Abstract We report a 59‐year‐old man with chronic myelogenous leukemia (CML) in chronic phase who presented with a large abdominal tumor. Biopsy revealed proliferation of granulocytic‐, erythroid‐, and megakaryocytic‐lineage cells in a retroperitoneal lymph node. The BCR/ABL fusion gene was detected on a paraffin‐embedded tissue section of the lymph node by double‐color fluorescence in situ hybridization, indicating an extramedullary hematopoietic tumor of CML origin. This patient has achieved a complete cytogenetic response for 19 months with imatinib mesylate (STI571; Gleevec), in association with the regression of the tumor. However, the development of an extramedullary tumor in chronic‐phase CML generally indicates a poor prognosis, because it commonly consists of blast proliferation and is followed by blast crisis in the marrow within a few months. This case, therefore, points to the importance of histological examination of extramedullary tumors in CML for evaluation of disease status and for therapeutic decisions. Am. J. Hematol. 77:167–170, 2004. © 2004 Wiley‐Liss, Inc.